Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
- 604 Downloads
Anthracyclines and taxanes are active cytotoxic drugs in the treatment of early metastatic breast cancer. It is yet unclear whether addition of capecitabine to the combination of these drugs improves the treatment outcome. Patients with advanced breast cancer were randomized to first-line chemotherapy with a combination of epirubicin (Farmorubicin®) and paclitaxel (Taxol®) alone (ET) or in combination with capecitabine (Xeloda®, TEX). Starting doses for ET were epirubicin 75 mg/m2 plus paclitaxel 175 mg/m2, and for TEX epirubicin 75 mg/m2, paclitaxel 155 mg/m2, and capecitabine 825 mg/m2 BID for 14 days. Subsequently, doses were tailored related to side effects. Primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), time to treatment failure (TTF), objective response (OR), safety and quality of life (QoL). 287 patients were randomized, 143 to ET and 144 to TEX. Median PFS was 10.8 months for patients treated with ET, and 12.4 months for those treated with TEX (HR 0.84, 95% CI 0.65–1.07, P = 0.16); median OS was 26.0 months for women in the ET versus 29.7 months in the TEX arm (HR 0.84, 95% CI 0.63–1.11, P = 0.22). OR was achieved in 44.8% (ET) and 54.2% (TEX), respectively (χ2 3.66, P = 0.16). TTF was significantly longer for patients treated with TEX, 6.0 months, versus 5.2 months following ET (HR 0.73, 95% CI 0.58–0.93, P = 0.009). Severe hematological side effects related to epirubicin and paclitaxel were evenly distributed between the treatment arms, mucositis, diarrhea, and Hand-Foot syndrome were significantly more frequent in the TEX arm. Toxicity-adjusted treatment with ET and TEX showed similar efficacy in terms of PFS, OS, and OR. In this trial with limited power, the addition of capecitabine to epirubicin and paclitaxel as first-line treatment did not translate into clinically relevant improvement of the outcome.
KeywordsAdvanced breast cancer First-line treatment Epirubicin Paclitaxel Capecitabine
Members of the Independent Review Committee Prof. Lars Holmberg, Division of Cancer Studies, King’s College, London, UK, Assoc. Prof. Torgil Möller, Dept of Cancer Epidemiology, Lund University, Sweden, and Prof. Erik Wist, Oslo University Hospital, Oslo, Norway, for constructive discussions during the study.
Unrestricted grants from Bristol-Myers Squibb Sweden AB, Pfizer Sweden AB and Roche Sweden AB, the Research Funds at Radiumhemmet, the Swedish Cancer Society, the Swedish Breast Cancer Association (BRO) and ALF/FOU research funds at the Karolinska Institutet and Stockholm County Council.
Conflict of interest
T. Hatschek: Consulting/advisory role: Pfizer; Funding: Roche, Sanofi-aventis. L. Carlsson: None. Z. Einbeigi: None. E. Lidbrink: None. B. Linderholm: None. B. Lindh: None. N. Loman: None. M. Malmberg: None. S. Rotstein: None. M. Söderberg: Consultant/advisory role: BMS, Roche. M. Sundquist: None. T. M. Walz: None. M. Hellström: None. K. Hammarlund: None. H. Svensson: None. G. Åström: None. Y. Brandberg: None. J. Carstensen: None. M. Fernö: None. J. Bergh: Consultant/advisory role: Amgen, Astrazeneca, GlaxoSmithKline, Pfizer, Sanofi-aventis; Funding: Amgen, Merck, Sanofi-aventis.
- 9.Mansutti M, Cavazzini G, Lorusso V, Boni C et al (2008) Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC). J Clin Oncol 26:49s (May 20 suppl; abstr 1034)Google Scholar
- 15.Jassem J, Pienkowski T, Pluzanska A, Jelic S et al (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19:1707–1715PubMedGoogle Scholar
- 17.Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2—positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 23:4265–4274PubMedCrossRefGoogle Scholar
- 18.Therasse P, Arbuck SG, Eisenhauer EA, Wanders J et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
- 19.WHO (1979) WHO Handbook for reporting results of cancer treatment. World Health Organization. WHO Offset Publication No. 48, GenevaGoogle Scholar
- 20.Collett D (1994) Modelling survival data in medical research. Chapman & Hall, London, p 255Google Scholar
- 21.Butters DJ, Ghersi D, Wilcken N, Kirk SJ et al (2010) Addition of drug/s to a chemotherapy regimen for metastatic breast cancer (Review). The Cochrane Collaboration. Wiley, ChichesterGoogle Scholar
- 22.Ghersi D, Wilcken N, Simes J, Donoghue E (2008) Taxane containing regimens for metastatic breast cancer (Review). The Cochrane Collaboration. Wiley, ChichesterGoogle Scholar
- 23.Biganzoli L, Cufer T, Bruning P (2002) Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 20:3114–3121PubMedCrossRefGoogle Scholar
- 28.Gamelin E, Delva R, Jacob J, Merrouche Y et al (2008) Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol 26:2099–2105PubMedCrossRefGoogle Scholar